Journal of Clinical Nutrition 2016;8(1):29-35
doi:10.15747/jcn.2016.8.1.29
Effect of Fish Oil-based Intravenous Fat Emulsion with Parenteral Nutrition in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Ji Hyeong CHOE 1 ; Young Joo LEE ; Hye Jung BAE ; Sun Hoi JUNG ; Hyeon Joo HAHN ; Yungil KOH
Affiliations
Keywords
Fatty acids; Fish oils; Hematopoietic stem cell transplantation; Parenteral nutrition; total
Country
Republic of Korea
Language
Korean
MeSH
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
Abstract
PURPOSE: Omega-3 fatty acid is known for immunonutrition in that it has anti-inflammatory properties and improves the patients' immune function. The objective of this study was to determine the effects of a fish oil-based lipid emulsion for adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: This was a retrospective study of 90 adult allogeneic HSCT patients from July 2011 to June 2015. The patients were divided into two groups according to the lipid type provided; fish oil group (FO group, n=55) and non-fish oil group (NFO group, n=35). The demographics, parenteral nutrition and lipid emulsion duration, length of hospital stay (LOS), weight change, 30 day mortality, survival period, incidence of acute graft-versus-host disease (aGVHD), neutropenic fever, sepsis, and re-hospitalization were collected from the electronic medical records. RESULTS: The patients' characteristics including age, sex, body mass index, and underlying disease were similar in the two groups. The incidence of aGVHD and infectious complications, mortality, LOS, re-hospitalization were also similar. The FO group showed weight gains, whereas the NFO group showed weight loss (FO vs. NFO=0.34% vs. -1.08%, P=0.245). CONCLUSION: The clinical outcomes were similar in the two groups but there was a tendency for gain weight in the FO group. A large, well designed study, and a dosing study will also be needed to determine the optimal dose range for HSCT patients.
备案号: 11010502037788, 京ICP备10218182号-8)